| 技术与方法 |
|
|
|
|
| 融合蛋白GGH粉针剂制备工艺研究 |
| 钱建瑛, 许正宏, 窦文芳 |
| 江南大学药学院 无锡 214122 |
|
| Study on the Preparation Technology of Injectable Powder of Fusion Protein GGH |
| QIAN Jian ying, XU Zheng hong, DOU Wen fang |
| School of Pharmaceutical Science, Jiangnan University, Wuxi 214122, China |
| [1] Hui H, Zhao X, Perfetti R. Structure and function studies of glucagon-like peptide-1(GLP-1):the designing of a novel pharmacological agent for the treatment of diabetes. Diabetes Metab Res Rev,2005,21(2):313-331.
[2] Drucker D J. Minireview:the glucagon-like peptides. Endocrinology,2001,142(2):521-527.
[3] Kreymann B, Williams G, Ghatei M A,et al. Glucagon-like peptide-17-36:a physiological incretin in man.Lancet,1987,2(8571):1300-1303.
[4] Vahl T P, Paty B W, Fuller B D, et al. Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1-(9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. Clin Endocrinol Metab,2003,88(4):1772-1779.
[5] Turton M D, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature,1996,379(6560):69-72.
[6] Deacon C F, Wamberg S, Bie P, et al. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol,2002,172(2):355-362.
[7] Pospisilik J A, Stafford S G, Demuth H U, et al. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucoseresponsi-veness in VDF (fa/fa) Zucker rats. Diabetes,2002,51(4):943-950.
[8] Deacon C F, Johnsen A H, Holst J J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab,1995,80(3):952-957.
[9] 窦文芳.长效融合蛋白GGH的构建、表达、纯化及其初步药效学和药代动力学.无锡:江南大学,生物工程学院,2010:1-59. Dou W F. Construction, Expression and Purification of the Long-term Fusion Protein GGH and Its Preliminary Pharmacodynamic and Pharmacokinetics. Wuxi:Jiangnan University,School of Biotechnolog,2010:1-59.
[10] 耿燕,任怡琳,许正宏,等.基于胞内cAMP浓度测定融合蛋白GGH活性的改良方法.中国生物工程杂志,2013,33(11):63-67. Geng Y, Ren Y L, Xu Z H, et al. An improved method to measure bioactivity of the fusion protein GGH based on the intracellular cAMP level. China Biotechnology, 2013,33(11):63-67.
[11] 胡雄伟,宋洪涛.核黄素磷酸钠粉针剂处方及制备工艺研究.解放军药学学报,2011,27(4):314-317. Hu XW, Song H T. A study on the formulation and preparation technology of riboflavin sodium phosphate injectable powder. Pham J Chin PLA, 2011,27(4):314-317.
[12] 那伊,阿凯尔斯.蛋白质药物——开发与生产. 北京:化学工业出版社,2006:35-37. Nail S L, Akers M J.Development and Manufacture of Protein Pharmaceuticals. Beijing, Chemical Industry Press,2006:35-37.
[13] 丁晓丽,张金亮,张慧,等.重组胰高血糖素样肽-1受体激动剂(rExendin-4)原液质量研究. 中国新药杂志,2015,2(12):1358-1363. Ding X L,Zhang J L,Zhang H,et al. Study on the quality of bulk solution of recombinant pancreatic glucagon-like peptide-1 receptor agonist(rExendin-4). Chinese Journal of New Drugs, 2015,2(12):1358-1363.
[14] 徐岩.干扰素α2b-29肽融合蛋白的制剂处方筛选及稳定性研究.哈尔滨:东北农业大学,生命学院,2013:18-20. Xu Y. Formulation and Stability Study of Interferon α2b-endothelial Inhibitory Peptide Fusion Protein. Ha'erbin:Northeast Agricultural University, College of Life Science,2013:18-20.
[15] 于忠喜.重组人生长激素冻干配方筛选和稳定性研究.长春:吉林大学,生命科学学院,2012:34-43. Yu Z X. Screening and Stability Study of Freeze-drying Formula for Recombinant Human Growth Hormone. Changchun:Jilin University,College of Life Science,2012:34-43.
[16] 罗文.rIL2-HSA融合蛋白注射剂型的开发研究.无锡:江南大学,药学院,2012:48-49. Luo W. Research on Injection Formulation of the Fusion Protein of rIL2-HSA. Wuxi:Jiangnan University,School of Pharmaceutical Sciences,2012:48-49.
[17] 田洪斌.注射用艾塞那肽冻干粉针剂的研究. 长春:吉林大学,生命科学学院,2008:33-36. Tian H B. The Study on Exenatide Freeze-dried Powder for Injection. Changchun:Jilin University,College of Life Science,2008:33-36. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
